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Abstract. Urinary citrate is a potent inhibitor of cal-
cium oxalate (CaOx) crystallization, but oral citrate
has rarely been used in patients with primary hyperox-
aluria (PH). We studied the effect of sodium citrate
administration (0.1-0.15 g/kg/day) on urinary citrate
excretion and CaOx saturation in seven paediatric
patients and the clinical response to long-term treat-
ment (average 4 years) in five patients. Urinary citrate
increased from 0.73 to 2.54 mmol/24h/l .73 m2 and
urinary saturation for CaOx (calculated by equil 2)
decreased from 11.41 to 6.79 (for both, p<0.02).
Long-term administration of alkali citrate [0.15 g
(0.5mmol)/kg/day] resulted in stable or improved
renal function in three and slow deterioration in two
partially non-compliant patients. Alkali citrate is
effective in patients with PH.
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Introduction
The goal of treating patients with primary hyperoxalu-
ria (PH) is to inhibit deposition of calcium oxalate
(CaOx) in the renal interstitium and to prevent renal
stone formation. Several drugs (e.g. magnesium, phos-
phate, methylene blue, thiazides) have been advocated
for this purpose, but little evidence of the efficacy has
been provided—with the exception of pyridoxine, to
which a minority of patients with PH type 1 is respons-
ive [1]. Oral citrate administration has only occasion-
ally been used in PH despite its known action as an
important inhibitor of CaOx crystallization [2,3]. In
view of the apparent positive clinical experience with
potassium citrate administration in adult patients with
idiopathic CaOx nephrolithiasis [4], we studied the
effect of alkali citrate in paediatric patients with PH
type 1 (PHI) [5]. This report extends our previous
findings and includes a larger number of urine
examinations.
Methods
The effect of sodium citrate administration (0.1-0.15 g/kg
body weight/day) was assessed in seven children with PHI
after they had been on or off this treatment for at least 14
days. The clinical response to long-term administration of
alkali citrate [sodium citrate or sodium potassium citrate
(Uralyt-U, Madaus) 0.15 g/kg body weight; phosphate cit-
rate 0.1 g/kg (Phosphate Sandoz) in patient 3] was assessed
in five of them. Urine collections (24 h) and chemical analysis
of urine were done as described previously [5] except that
citrate was measured by ion chromatography. The mean
citrate excretion and CaOx saturation (calculated by equil 2
[6]) were determined in each patient without oral citrate and
during citrate administration (in total, 17 and 51 urine
samples, respectively). The mean value for the whole group
was calculated from the means of the individual patients.
Results
Citrate excretion in the urine (Table 1) was in the
normal range in two and very low in five patients
before citrate administration and increased in all seven
to values in the normal range [7,8]. The urinary CaOx
saturation before oral citrate administration was uni-
formly elevated above the normal range for age and
gender [8] and decreased in each instance, although
not reaching the normal range in four patients
(Table 1). Both the increase of the mean citrate
Table 1. Effect of sodium citrate administration in seven patients
with PHI
Patient
i
2
3
4
5
6
7
Gender
m
f
m
f
m
f
m
Age
(yean)
15
8
10
10
2
12
15
Urinary citrate1
No oral
citrate
0.12
0.68
1.61
0.69
0.47
0.38
1.19
1 Oral
citrate
1.63
1.65
4.33
2.17
2.17
4.01
1.82
CaOx saturation
No oral
citrate
11.67
10.51
11.48
15.03
9.97
10.57
10.63
Oral
citrate
9.06
7.84
5.34
9.31
4.37
2.72
8.87
Normal2
<6.0
<62
<7.7
<6.2
<8.0
<62
<6.0
Correspondence and offprint requests to: Prof. E. Leumann, University ' m m o l ^ h/1.73 m3.
Children's Hospital, Steinwiesstr. 75, CH 8032 Zurich, Switzerland. fo rma l (X+SEM) for gender and age [8].
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excretion from 0.73 to 2.54 mmol/day/1.73 m2 and the
decrease of the mean saturation from 11.41 to 6.79
were statistically significant (P<0.02; one-sample
Wilcoxon test) (Fig. 1).
During oral citrate administration for 24-68 (aver-
age 47) months, renal function, as estimated from
serum creatinine, remained stable or improved in three
patients, and slowly deteriorated in two (Fig. 2). These
two male teenagers were intermittently non-compliant,
as demonstrated by the strong variations of the urinary
pH and the urinary citrate excretion. Clinically, all
four patients with repeated attacks of colicky pain
before citrate administration had fewer episodes of
passage of renal stones (Patient 1 from 2.8 to 0.6 per
month). Patient 2 was anorectic when citrate was
temporarily discontinued.
There were no apparent adverse effects of citrate
administration; plasma bicarbonate was in the normal
range or slightly elevated (24-28 mmol/1).
15
p<0.02
p<0,02
d No citrate
Fig. 1. Effect of citrate administration on citrate excretion and CaOx
saturation.
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Fig. 2. Serum creatinine during citrate administration. Patients are
identified by numbers.
Urinary citrate is a potent inhibitor of CaOx crystal-
lization by complexing with calcium and thus lowering
the ionic calcium concentration [2,3]. This effect is
more pronounced at a higher pH G>7) where citrate
is predominantly trivalent, in contrast to pH 5 (only
one negative charge). In order to have the maximum
effect it is therefore necessary to increase both the
urinary pH and the urinary citrate excretion. Most of
the administered citrate is metabolized to bicarbonate,
but a fraction of the absorbed citrate may escape
metabolic degradation and appear directly in the urine
[3,9]. More citrate is excreted during metabolic alkal-
osis as a result of lower tubular reabsorption of filtered
citrate (normal plasma concentration 0.1 mmol/1)
[3,9]. Sodium chloride loading depresses urinary citrate
excretion [10], whereas a large vegetable fibre intake
and high urine volume have the opposite effect in adult
calcium stone formers with hypocitraturia [11].
Potential disadvantages of prescribing sodium citrate
are the added osmotic load and, possibly, an increased
intestinal absorption of oxalate, since sodium oxalate
is more soluble than calcium oxalate. Therefore, it
might be preferable to use sodium potassium citrate
as long as there is no severe renal insufficiency. Dietary
sodium intake should be restricted. Thiazides—occa-
sionally prescribed in PH because of their hypocalciuric
effect—depress urinary citrate excretion by inducing
hypokalaemia with intracellular acidosis [3]. Poor
compliance was a critical issue in our adolescent
patients. Sodium or sodium potassium citrate (in
powder form or tablets) is not particularly attractive;
sodium potassium citrate, now available as effervescent
tablets (Madaus), is not accepted by all paediatric
patients. Therefore, a close follow-up with regular
monitoring of the urinary pH, volume and citrate
excretion is necessary.
Administration of alkali citrate will not fully prevent
deposition of CaOx in the kidney, although the demon-
strated lowering of the CaOx saturation appears
straightforward. Indeed, saturation was not normalized
in all patients. Additional measures, notably a large
fluid intake and early diagnosis, are crucial to prevent
renal insufficiency which also depresses urinary citrate
excretion [7,12]. Further experience in more patients
is certainly needed in PHI, a disease carrying a pro-
gnosis that is difficult to predict. PHI has great geno-
typic, enzymatic and clinical heterogeneity. Enzymatic
activity correlates poorly with clinical manifestation
[1]. Therefore, the importance of other factors, includ-
ing environmental ones, must not be underscored.
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Note added in proof
Milliner etal. [13] report long-term results with orthophosph-
ate and pyridoxine in PH. Three of their nine patients with
PHI were pyridoxine-sensitive. Effervescent phosphate tab-
lets also contain citrate [5].
